Juan Miguel Mosquera
Overview
Explore the profile of Juan Miguel Mosquera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
125
Citations
8754
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Delgado-de la Mora J, Al Assaad M, Karaaslan S, Hadi K, Halima A, Deshpande A, et al.
Pathol Res Pract
. 2025 Feb;
266:155825.
PMID: 39893087
No abstract available.
2.
Madorsky Rowdo F, Martini R, Ackermann S, Tang C, Tranquille M, Irizarry A, et al.
Cancer Res
. 2025 Feb;
85(3):551-566.
PMID: 39891928
Precision medicine approaches to cancer treatment aim to exploit genomic alterations that are specific to individual patients to tailor therapeutic strategies. Yet, some targetable genes and pathways are essential for...
3.
Guevara D, Shin N, Boiko A, Valiev I, Elsaeed A, Mosquera J, et al.
Anticancer Res
. 2025 Jan;
45(2):613-618.
PMID: 39890191
Background/aim: Urothelial carcinoma, common in older adults, is rare in younger populations and even less common in the prostatic urethra. Advanced disease is typically managed with platinum-based chemotherapy, immune checkpoint...
4.
Guevara D, Shin N, Boiko A, Valiev I, Elsaeed A, Mosquera J, et al.
Anticancer Res
. 2025 Jan;
45(2):619-623.
PMID: 39890190
Background/aim: Mesonephric adenocarcinoma in males is an exceptionally rare malignancy arising from mesonephric remnants. Accurate diagnosis requires thorough histopathological and molecular analysis. Case Report: A 33-year-old male presented with right...
5.
Claridge S, Nath S, Baum A, Farias R, Cavallo J, Rizvi N, et al.
Clin Transl Med
. 2025 Jan;
15(2):e70078.
PMID: 39856363
Background: The goal of precision oncology is to find effective therapeutics for every patient. Through the inclusion of emerging therapeutics in a high-throughput drug screening platform, our functional genomics pipeline...
6.
Delgado-de la Mora J, Al Assaad M, Karaaslan S, Hadi K, Halima A, Deshpande A, et al.
Pathol Res Pract
. 2024 Dec;
266:155798.
PMID: 39731868
Pancreatic acinar cell carcinoma (PACC) is a rare pancreatic tumor with a heterogeneous clinical course and, except for radical surgery, limited treatment options. We present a comprehensive study encompassing whole-genome...
7.
Windon A, Al Assaad M, Hadi K, Mendelson N, Hissong E, Deshpande A, et al.
Pathol Res Pract
. 2024 Dec;
266:155788.
PMID: 39708521
Background: Adenocarcinoma of the esophagus and stomach demands a deeper molecular understanding to advance treatment strategies and improve patient outcomes. Here, we profiled the genome and transcriptome landscape of these...
8.
Delgado-de la Mora J, Al Assaad M, Quitian S, Levine M, Deshpande A, Sigouros M, et al.
Pathol Res Pract
. 2024 Dec;
266:155782.
PMID: 39708519
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasm of the digestive tract. Despite multiple therapeutic advances, patients with advanced disease frequently develop resistance to tyrosine kinase inhibitors (TKIs),...
9.
Al Assaad M, Hadi K, Tu J, Levine M, Patel M, Deshpande A, et al.
Pathol Res Pract
. 2024 Dec;
266:155773.
PMID: 39673888
Background: Advanced-stage tube-ovarian cancers (TOC) and uterine cancers (UC) significantly contribute to cancer mortality. While surgery achieves clinical remission in most cases, recurrence often necessitates systemic therapy. Recent molecular phenotype...
10.
Kalomeris T, Al Assaad M, Delgado-de la Mora J, Gundem G, Levine M, Boyraz B, et al.
Pathol Res Pract
. 2024 Dec;
266:155725.
PMID: 39626581
Adrenocortical carcinoma (ACC) is a rare, aggressive malignancy with limited treatment options and poor prognosis, with a 5-year survival rate of about 15 %. This study used whole genome sequencing...